Platelet activation in essential hypertension during exercise: Pre-and post-treatment changes with an angiotensin ii receptor blocker

American Journal of Hypertension

Volumn 27, Issue 4, 2014, Pages 571-578

  Gkaliagkousi, Eugenia ^a   Gavriilaki, Eleni ^a   Yiannaki, Efi ^b   Markala, Dimitra ^b   Papadopoulos, Nikolaos ^a   Triantafyllou, Areti ^a   Anyfanti, Panagiota ^a   Petidis, Konstantinos ^a   Garypidou, Vasileia ^a   Doumas, Michael ^a   Ferro, Albert ^c   Douma, Stella ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Blood pressure; Essential hypertension; Exercise; Hypertension; Monocyte platelet aggregates; p selectin; Platelet activation

Indexed keywords

PADGEM PROTEIN; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; TETRAZOLE DERIVATIVE; VALINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; EXERCISE TEST; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MONOCYTE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREADMILL EXERCISE; YOUNG ADULT; ANALOGS AND DERIVATIVES; ARTERIAL WALL THICKNESS; DRUG EFFECTS; EXERCISE; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CAROTID INTIMA-MEDIA THICKNESS; EXERCISE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLATELET ACTIVATION; TETRAZOLES; VALINE;

EID: 84897897323     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt153     Document Type: Article

References (39)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
3. Gkaliagkousi E, Passacquale G, Douma S, Zamboulis C, Ferro A. Platelet activation in essential hypertension: implications for antiplatelet treatment. Am J Hypertens 2010; 23:229-236.
4. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104:1533-1537.
5. Burdess A, Michelsen AE, Brosstad F, Fox KA, Newby DE, Nimmo AF. Platelet activation in patients with peripheral vascular disease: reproducibility and comparability of platelet markers. Thromb Res 2012; 129:50-55.
6. Gkaliagkousi E, Corrigall V, Becker S, de Winter P, Shah A, Zamboulis C, Ritter J, Ferro A. Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. Eur Heart J 2009; 30:3048-3054.
7. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, Van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009; 18:308-347.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
9. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 2011; 57:2037-2114.
10. Dahabreh IJ, Paulus JK. Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis. JAMA 2011; 305:1225-1233.
11. Yilmaz MB, Saricam E, Biyikoglu SF, Guray Y, Guray U, Sasmaz H, Korkmaz S. Mean platelet volume and exercise stress test. J Thromb Thrombolysis 2004; 17:115-120.
12. Schernthaner G, Vukovich T, Knobl P, Hay U, Muller MM. The effect of near-normoglycaemic control on plasma levels of coagulation factor VII and the anticoagulant proteins C and S in insulin-dependent diabetic patients. Br J Haematol 1989; 73:356-359.
13. Petidis K, Douma S, Doumas M, Basagiannis I, Vogiatzis K, Zamboulis C. The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease. BMC Cardiovasc Disord 2008; 8:11.
14. Naesh O, Hindberg I, Trap-Jensen J, Lund JO. Post-exercise platelet activation-aggregation and release in relation to dynamic exercise. Clin Physiol 1990; 10:221-230.
15. Hendra TJ, Oughton J, Smith CC, Betteridge DJ, Yudkin JS. Platelet function in uncomplicated insulin-dependent diabetic patients at rest and following exercise. Diabet Med 1988; 5:469-473.
16. Rocker L, Gunay S, Gunga HC, Hopfenmuller W, Ruf A, Patscheke H, Mockel M. Activation of blood platelets in response to maximal isometric exercise of the dominant arm. Int J Sports Med 2000; 21:191-194.
17. Gibbs CR, Blann AD, Edmunds E, Watson RD, Lip GY. Effects of acute exercise on hemorheological, endothelial, and platelet markers in patients with chronic heart failure in sinus rhythm. Clin Cardiol 2001; 24:724-729.
18. Li N, He S, Blomback M, Hjemdahl P. Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin. Arterioscler Thromb Vasc Biol 2007; 27:407-413.
19. Hilberg T, Menzel K, Glaser D, Zimmermann S, Gabriel HH. Exercise intensity: platelet function and platelet-leukocyte conjugate formation in untrained subjects. Thromb Res 2008; 122:77-84.
20. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, Mark DB, Marwick TH, McCallister BD, Thompson PD, Winters WL Jr, Yanowitz FG, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Lewis RP, O'Rourke RA, Ryan TJ. ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Circulation 1997; 96:345-354.
21. White WB. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens Suppl 2003; 21:S9-S15.
22. Smith JE. Effects of strenuous exercise on haemostasis. Br J Sports Med 2003; 37:433-435.
23. Lijnen P, Fagard R, Staessen J, Amery A. Plasma prostaglandins, renin, and catecholamines at rest and during exercise in hypertensive humans. J Appl Physiol 1982; 53:891-894.
24. Tosti-Croce C, Lucarelli C, Betto P, Floridi A, Rinaldi R, Salvati A, Taggi F, Sciarra F. Plasma catecholamine responses during a personalized physical stress as a dynamic characterization of essential hypertension. Physiol Behav 1991; 49:685-690.
25. Predel HG, Mainka W, Schillings W, Knigge H, Montiel J, Fallois J, Agrawal R, Schramm T, Graf C, Giannetti BM, Bjarnason-Wehrens B, Prinz U, Rost RE. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. J Hum Hypertens 2001; 15:715-721.
26. Raber W, Raffesberg W, Waldhausl W, Gasic S, Roden M. Exercise induces excessive normetanephrine respo0es in hypertensive diabetic patients. Eur J Clin Invest 2003; 33:480-487.
27. Saitoh M, Miyakoda H, Kitamura H, Kinugawa T, Hisatome I, Kotake H, Mashiba H. Cardiovascular and sympathetic nervous response to dynamic exercise in patients with essential hypertension. Intern Med 1992; 31:606-610.
28. Doumas MN, Douma SN, Petidis KM, Vogiatzis KV, Bassagiannis IC, Zamboulis CX. Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension. J Clin Hypertens (Greenwich) 2004; 6:682-689.
29. Jindra A, Jr., Savlikova J, Bultas J. Relationship between plasma catecholamines and the renin-aldosterone system during exercise in normal and essential hypertensive subjects. Clin Exp Hypertens A 1990; 12:415-435.
30. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 2000; 11:61-69.
31. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 1994; 89:1951-1957.
32. Hjemdahl P, Larsson PT, Wallen NH. Effects of stress and beta-blockade on platelet function. Circulation 1991; 84:VI44-VI61.
33. Buckley C, Curtin D, Walsh T, O'Malley K. Ageing and platelet alpha 2-adrenoceptors. Br J Clin Pharmacol 1986; 21:721-722.
34. Esler M, Jennings G, Lambert G. Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens 1989; 2:140S-146S.
35. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010; 30:2341-2349.
36. Ferreira SH, Vane JR. Half-lives of peptides and amines in the circulation. Nature 1967; 215:1237-1240.
37. Dendorfer A, Raasch W, Tempel K, Dominiak P. Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic Res Cardiol 1998; 93:24-29.
38. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984; 2:581-587.
39. Schwieler JH, Kahan T, Wallen NH, Nussberger J, Hjemdahl P. Inhibition of the renin-angiotensin system does not reduce platelet activity at rest or during stress in hypertension. J Hypertens 2013; 31:1676-1682.